Good Morning Team.
Please enjoy my chat with Jeremy, above.
Poolbeg Pharma is a small-cap Irish biotech (market cap ~£44m) developing POLB 001, an oral p38 MAPK inhibitor designed to prevent Cytokine Release Syndrome (CRS) — a dangerous inflammatory side effect that affects over 70% of patients receiving CAR-T and bispecific antibody cancer therapies.
Rather than competing with these breakthrough immunotherapies, POLB 001 is designed as a supportive-care add-on that could theoretically pair with multiple CAR-T/bispecific products across different manufacturers, positioning it as a platform opportunity rather than a single-drug bet.
While p38 inhibitors have failed in chronic conditions before, Poolbeg argues CRS’s short, predictable treatment window (rather than indefinite dosing) sidesteps those historical failure modes.
The evidence base includes a peer-reviewed Phase 1b human challenge trial showing strong, dose-dependent cytokine reduction with a clean safety profile; supportive preclinical in vivo CRS data; and — critically — in vitro data suggesting POLB 001 doesn’t blunt bispecific antibodies’ tumour-killing effect, addressing the key objection any pharma partner would raise.
The company’s pivotal TOPICAL trial (in ~30 relapsed/refractory myeloma patients, using J&J-supplied teclistamab) is now dosing patients across NHS sites, with interim data expected late summer 2026 — the central near-term catalyst, benchmarked against historical CRS incidence rates rather than a placebo arm.
A secondary program, an oral encapsulated GLP-1 drug for obesity, offers a second, less central catalyst later in 2026.
Supporting the investment case - independent market research sizing peak sales in the billions, an expanding global patent estate (exclusivity potentially to 2044), FDA Orphan Drug Designation and positive pre-IND feedback, active partnering conversations with pharma companies, and J&J’s in-kind involvement (free drug supply, joint research programme) as a signal of pharma interest.
Management has a track record (prior sale of Amryt Pharma for >$1 billion), and the Executive Chairman has personally invested £1.5 million. A recent placing extended cash runway to Q2 2028, giving the company negotiating leverage rather than a funding-driven urgency heading into data readouts.
Poolbeg is a risk play, but one addressing a well-documented, unmet clinical gap with de-risking data accumulated across multiple study types, strong IP protection, and credible pharma engagement — all converging on a near-term (likely August/September 2026) data catalyst that could trigger a partnering deal or a re-rating.
As with all biotech investing, this carries risk and requires your independent due diligence.
But you should know that already.
